ImmunityBio (IBRX) News Today $2.60 +0.01 (+0.39%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.60 0.00 (-0.19%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period HC Wainwright Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX)September 12 at 8:19 AM | marketbeat.comImmunityBio (NASDAQ:IBRX) Stock Price Up 7.3% - Should You Buy?September 11 at 4:13 PM | marketbeat.comImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is TickingSeptember 11 at 12:26 PM | seekingalpha.comImmunityBio (NASDAQ:IBRX) Given Buy Rating at D. Boral CapitalSeptember 10 at 10:50 AM | marketbeat.comImmunityBio study shows ANKTIVA reverses lymphopenia, extends survivalSeptember 8, 2025 | msn.comA Closer Look at ImmunityBio (IBRX) Valuation Following Promising Early Results in Glioblastoma StudySeptember 6, 2025 | finance.yahoo.comImmunityBio, Inc. $IBRX Shares Sold by Rafferty Asset Management LLCSeptember 3, 2025 | marketbeat.comNuveen LLC Purchases New Position in ImmunityBio, Inc. $IBRXSeptember 3, 2025 | marketbeat.comImmunityBio (IBRX) Reports Initial Study Data Showing 100% Disease Control in Patients With Recurrent GlioblastomaAugust 31, 2025 | msn.comImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ PlatformAugust 28, 2025 | insidermonkey.comImmunityBio, Inc. $IBRX Shares Acquired by Swiss National BankAugust 28, 2025 | marketbeat.comWhat ImmunityBio (IBRX)'s Early Glioblastoma Disease Control Results Could Mean for ShareholdersAugust 27, 2025 | finance.yahoo.comInitial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® DeviceAugust 26, 2025 | mms.businesswire.comVanguard Group Inc. Has $61.24 Million Stock Position in ImmunityBio, Inc. $IBRXAugust 26, 2025 | marketbeat.comImmunityBio announces Anktiva trialAugust 20, 2025 | msn.comCitigroup Inc. Grows Stock Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)August 18, 2025 | marketbeat.com12 Best Healthcare Stocks to Buy Under $30August 17, 2025 | insidermonkey.comImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption AcceleratesAugust 17, 2025 | msn.comImmunityBio (NASDAQ:IBRX) Trading Down 5.5% - Should You Sell?August 16, 2025 | marketbeat.comImmunityBio's (IBRX) Buy Rating Reiterated at D. Boral CapitalAugust 16, 2025 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Time to Buy?August 15, 2025 | marketbeat.comImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX)August 15, 2025 | marketbeat.comImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate ResultsAugust 15, 2025 | msn.comImmunitybio stock soars after promising cancer therapy trial resultsAugust 13, 2025 | investing.comImmunityBio announces early findings from QUILT-106 trialAugust 13, 2025 | msn.comImmunityBio higher after early-stage trial results for cell therapy in lymphomaAugust 13, 2025 | msn.comImmunityBio’s Shareholder Settlement Gains Preliminary ApprovalAugust 11, 2025 | theglobeandmail.comImmunityBio FY2026 EPS Estimate Decreased by HC WainwrightAugust 9, 2025 | marketbeat.comImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral CapitalAugust 6, 2025 | marketbeat.comIBRX Sales Soar 2,540%August 5, 2025 | fool.comImmunityBio (IBRX) to Release Earnings on MondayAugust 5, 2025 | marketbeat.comImmunityBio (IBRX) Announces Preliminary Financial Results for the Quarter Ended June 30August 4, 2025 | msn.comImmunitybio (IBRX) Targets $80 Million Capital Raise for Business OperationsAugust 1, 2025 | finance.yahoo.comImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder CancerJuly 31, 2025 | finance.yahoo.comImmunityBio, Inc. (IBRX) Gains UK Approval for ANKTIVA in Bladder CancerJuly 31, 2025 | insidermonkey.comImmunityBio (NASDAQ:IBRX) Stock Price Down 6.1% - Here's What HappenedJuly 26, 2025 | marketbeat.comImmunityBio's (IBRX) "Buy" Rating Reiterated at D. Boral CapitalJuly 26, 2025 | marketbeat.comImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory UpdatesJuly 25, 2025 | businesswire.comImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple ...July 25, 2025 | gurufocus.comImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional InvestorsJuly 25, 2025 | businesswire.comImmunityBio (NASDAQ:IBRX) Trading Up 10.9% - Here's What HappenedJuly 24, 2025 | marketbeat.comLA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old PaperJuly 22, 2025 | benzinga.comImmunityBio: Still Flashing Signs Of Life After Another Anktiva ApprovalJuly 21, 2025 | seekingalpha.comImmunityBio: High Stakes On Anktiva's Growth Amidst FDA Friction And Financial PressuresJuly 12, 2025 | seekingalpha.comImmunityBio’s Innovative Approach to Ovarian Cancer: A Phase 2 Study UpdateJuly 9, 2025 | tipranks.comUK MHRA Approves ImmunityBio's ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In SituJuly 7, 2025 | businesswire.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Here's What HappenedJuly 7, 2025 | marketbeat.comBullish Sentiments for ImmunityBio (IBRX) After Trial Success and FDA AuthorizationJuly 7, 2025 | msn.comImmunityBio (IBRX) Rated Buy After FDA Approvals and Pancreatic Cancer Trial SuccessJuly 2, 2025 | msn.comImmunityBio (IBRX) Attains FDA’s Expanded Access Authorization for its Cancer BioShield Platform Anchored by ANKTIVAJune 24, 2025 | msn.com Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.540.92▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼94▲IBRX Articles Average Week Get the Latest News and Ratings for IBRX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for ImmunityBio and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ELAN News ROIV News RVMD News RYTM News GRFS News LEGN News ABVX News AXSM News RNA News CYTK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
